EXCLUSIVE: Irwin Naturals CEO Explains Importance Of Brand In Booming Psychedelics Space

  • One of the challenges faced by the psychedelics industry is that trauma and mental illness are tied to income, yet off-label ketamine treatment is not yet covered by insurance, Klee Irwin, founder, CEO, & chairman of Irwin Naturals IWINF told the inaugural Benzinga Psychedelics Capital Conference on Tuesday.

    Is there a solution? The Power Of Brand 

    According to Irwin, “The solution is to use the power of brand to drive down patient costs.”

    Irwin Naturals is considered the world’s largest seller of CBD in the mass market, and this year it is extending its brand to psychedelics and THC. Irwin Natural’s nutraceutical products are sold in large outlets across America, including Costco COSTWalmart WMT, and Whole Foods. The brand seeks to make itself familiar to 80% of U.S. households. 

    “We intend to be the world's first truly household name brand, with a national and then international footprint in clinics,” added Irwin, explaining that 28-year run rate of profitability is enabling the company to have the “rare Coca-Cola KO first-mover advantage.”

    Brands are important because consumers are not buying products or services, they are buying brands.

    Two Brand Classes

    There will be two brand classes in this disruptive industry of psychedelic mental health, according to Irwin. First – major drug brands, and second - major national clinic chain brands that employ doctors the pharmaceutical companies must go through to get their drugs into the hands of patients.

    “Building a household name brand is very expensive and it takes decades of presence in the market. But once a household name brand is established, operating costs can go down precipitously,” he noted, pointing out that lower operating expenses automatically are passed onto patients and third-party payers, so accessibility increases.

    The Potential Of The Psychedelics Industry

    How big is this opportunity?

    It seems that some 25% of adults have a diagnosable mental illness like insomnia, anxiety, subclinical PTSD, depression – all of whom could benefit from psychedelics treatment. This means that we need “a heck of a lot more than the 600 ketamine clinics.”

    Doing Good Above All

    For Irwin, doing good should come first. He called the mental health crisis scarier than the chance of nuclear holocaust. 

    “We need to take care of the people in our society who are suffering the most, and leveraging brand is the way to do it,” Irwin concluded. 

Photo: Courtesy of Nick Fewings on Unsplash

Related Links:

Irwin Naturals Introduces Suite Of Clinic Services For Mental Health Solutions

Irwin Naturals Acquires Ketamine Clinic Midwest Ketafusion

Posted In: CannabisNewsPenny StocksPsychedelicsEventsExclusivesMarketsBenzinga Psychedelics Capital ConferenceKlee IrwinPCCPCC22

Missed the first wave of cannabis investments? Don’t make that mistake again.

Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.

Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!

Just this year, the PotProfits portfolio has seen smoking-hot gains like:

  • 47.10% with $GTBIF
  • 40.23% with $TCNNF
  • 21.50% with $VFF

But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.

Don't miss out on the green rush!